|By Marketwired .||
|December 5, 2013 07:00 AM EST||
TORONTO, ONTARIO -- (Marketwired) -- 12/05/13 -- Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) (OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced it will be providing an update on its immune checkpoint program targeting the CD47 protein at the 55th Annual Meeting of the American Society of Hematology, which will be held December 7-10, 2013 in New Orleans, LA. Details of the poster presentation, entitled "Blockade of CD47 Using SIRPaFc: Role of the Fc Region in Anti-Leukemic Activity", are listed below:
Date: Monday December 9, 2013 Time: 6:00 - 8:00 pm (CST) 615. Acute Myeloid Leukemia: Therapy, excluding Transplantation: Session: Poster III Abstract #: 3935 Presenter: Dr. Robert Uger, Chief Scientific Officer Location: Hall E, Ernest N. Morial Convention Center, New Orleans, LA
About Stem Cell Therapeutics:
Stem Cell Therapeutics Corp. (SCT) is an immuno-oncology company advancing cancer stem cell discoveries into novel and innovative cancer therapies. Building on over half a century of leading and groundbreaking Canadian stem cell research, the company is supported by established links to a group of prominent Toronto academic research institutes and cancer treatment centers, representing one of the world's most acclaimed cancer research hubs. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on cancer stem cells in AML and several other tumors. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors. SCT's clinical stage programs include the recently in-licensed program focused on the structure of tigecycline, which is currently being evaluated in a multi-centre Phase I study in patients with acute myeloid leukemia (AML), as well as TTI-1612, a non- cancer stem cell asset that recently completed a 28-patient Phase I trial in interstitial cystitis ("IC") patients. For more information, visit: www.stemcellthera.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.